Clinical Trial Update: A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy [Phase 3]

View source ↗

Summary

Phase 3 study of Aticaprant 10 mg as adjunctive therapy for adults with major depressive disorder and anhedonia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anhedonia
• Major Depressive Disorder

Drugs mentioned

• Aticaprant (Aticaprant)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depressive Disorder, Major, Anhedonia | Phase 3 | Status: COMPLETED | Results posted: 2026-01-02